Avera Pharmaceuticals, Inc. Completes Successful Phase 2 Study Of Gantacurium Chloride For Endotracheal Intubation

Published: Jun 27, 2006

SAN DIEGO--(BUSINESS WIRE)--June 27, 2006--Avera Pharmaceuticals, Inc., a privately held pharmaceutical company developing medicines that act on the nervous system, today announced the successful completion of a Phase 2 clinical study of gantacurium chloride as an adjunct to general anesthesia to enable rapid intubation of patients undergoing surgery. Gantacurium chloride is a new, investigational, non-depolarizing ultra-short acting neuromuscular blocker.

Back to news